跳至主要内容
临床试验/NCT01753830
NCT01753830终止不适用

A Multi Center, Randomized, Double Blind, Saline Controlled Study of a Single Injection of Durolane® Versus a Single Injection of Phosphate Buffered Saline (PBS) to Treat Pain Associated With Osteoarthritis of the Knee

Galderma R&D25 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2012年12月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
Galderma R&D
入组人数
75
试验地点
25
主要终点
Average Change in WOMAC VAS Pain Score From Week 6 to Week 30

研究概览

简要总结

The purpose of the study is to determine whether a single intra-articular injection of Durolane 4.5 mL is superior to a single injection of PBS 4.5 mL for the relief of joint pain in patients with osteoarthritis of the knee.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Body Mass Index (BMI) ≤ 35 kg/m2
  • Symptomatic osteoarthritis (OA) of the knee
  • K L severity grade 1 or 2
  • If bilateral OA, contralateral knee K L severity grade 0 or 1

排除标准

  • Has clinically apparent tense effusion of the index knee
  • Has had surgery on the symptomatic knee within the previous 12 months or arthroscopy in the index knee in the past 3 months
  • Has any painful orthopedic disorders of the back or hip
  • Has a joint disorder other than osteoarthritis in the index knee

结局指标

主要结局

Average Change in WOMAC VAS Pain Score From Week 6 to Week 30

时间窗: Up to 30 weeks

Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain score (0-100 mm Visual Analogue Scale (VAS)). Lower score mean less pain.

次要结局

未报告次要终点

研究者

发起方
Galderma R&D
申办方类型
Industry
责任方
Sponsor

研究点 (25)

Loading locations...

相似试验